Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab for advanced endometrial cancer
ACTRN12617000106336Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Feb 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in endometrial cancer (EC), sponsored by University of Sydney. Primary endpoint: Objective tumour response rate by iRECIST. Started Feb 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ACTRN12617000106336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000106336.